Sub-millimeters matter. Choose CyberKnife® precision. When it comes to the delicate and complex tissues and structures of the brain, precision matters.
The CyberKnife System gives you a proven, non-surgical option for treating your brain tumor that may help minimize to minimize the risk of potential side effects that can impact short- and long-term quality of life.
Delivering stereotactic radiosurgery (SRS) treatments with unrivaled, sub-millimeter accuracy, the CyberKnife provides excellent clinical outcomes in treating a wide range of brain tumors — in fewer visits.
Key CyberKnife treatment benefits:
Non-surgical and non-invasive
No head frame is required
Good cancer control
Reduced incidence of common cognitive side effects
Treatments may be completed in as little as 1-5 sessions within 1-2 weeks
Most patients can continue normal activity throughout treatment
Typically does not require interruption of chemotherapy cycles or immunotherapy treatments
Patients previously treated with whole brain radiotherapy may be candidates for CyberKnife SRS treatment
Patients previously treated with SRS may be candidates for CyberKnife SRS in other areas of the brain
More than two decades of clinical proof
The revolutionary CyberKnife treatment technology is not new; the CyberKnife System has more than two decades of clinical proof and has helped thousands of patients with various brain tumors and metastases.
The CyberKnife System is routinely used to treat conditions in the brain including, but not limited to, benign and malignant primary tumors, brain metastases, trigeminal neuralgia, acoustic neuromas and arteriovenous malformations (AVMs).
CyberKnife radiosurgery is even used to treat complicated neurosurgical cases, while maximally sparing healthy brain tissues involved in important functions such as motor control, touching, hearing and vision.
Demonstrated clinical benefits in the treatment of brain cancers and metastases:
CyberKnife SRS has been proven safe and effective for a broad range of neurological indications including brain and spinal tumors, meningioma, acoustic neuroma, pituitary adenomas, vascular malformations, and functional disorders.
In a clinical study of 133 patients treated for tumor metastases to the brain presenting with clinical symptoms such as headaches and seizures, 90 percent of patients either stabilized or improved performance status following treatment with the CyberKnife System.
In a clinical study of 333 patients using the CyberKnife System to treat tumor metastases to the brain, more than 85 percent of evaluable patients achieved local tumor control at two years post treatment. That is, the tumor either decreased in size or stopped growing.
CyberKnife frameless SRS also offers a precise, non-invasive treatment with clinical outcomes comparable to Gamma Knife frame-based SRS as demonstrated on patients treated with brain metastases and trigeminal neuralgia.
A clinical study of 199 patients whose lesions were unsuitable for treatment with surgery and/or a portion of the lesion remained after surgery found that more than 92 percent of patients either experienced stabilization or a significant improvement of their symptoms following treatment with the CyberKnife System.
Brain tumor patients are among the most treated at CyberKnife Miami with good success rates. Call our team at 305-279-2900 to set up a consultation to find out if we can help you.